Ministry of Chemicals and Fertilizers

1. Urea Subsidy (CS)

1. Nodal Ministry & Department

• • Ministry: Ministry of Chemicals and Fertilizers.
  • Department: Department of Fertilizers.

2. Context

• • Status: India’s only fertilizer under direct statutory price control.
  • Why: To ensure the availability of urea—the most used nitrogenous fertilizer—at a constant, affordable price to farmers regardless of international price volatility.
  • 2026 Update: The Union Budget 2026-27 allocated ₹1.26 lakh crore specifically for the urea subsidy (out of a total fertilizer subsidy of ₹1.71 lakh crore). This includes additional funding to manage the price shocks caused by the West Asia crisis (2025-26).

3. Objectives

• • To provide urea to farmers at a statutory controlled Maximum Retail Price (MRP).
  • To achieve “Atmanirbharta” (Self-sufficiency) in urea production by 2026-27.
  • To promote balanced soil nutrition by integrating conventional urea with Nano-urea.

4. Type of Scheme

• • Central Sector Scheme (100% funded by the Central Government).

5. Target Beneficiaries

• • All farmers across India.
  • Domestic fertilizer manufacturing units (Public, Cooperative, and Private sectors).

6. Eligibility Criteria

• • Farmers must purchase urea through authorized retailers using the Integrated Fertilizer Management System (iFMS).
  • Aadhaar-based authentication at the Point of Sale (PoS) machine is required to verify the sale.

7. Key Features/Provisions

• • Pricing: The MRP is fixed by the Government (currently ₹242 per 45 kg bag, exclusive of taxes/neem coating charges). The difference between the production/import cost and the MRP is paid to companies as a subsidy.
  • Direct Benefit Transfer (DBT): Unlike other sectors where the user gets cash, in fertilizers, 100% of the subsidy is released to the companies only after the actual sale is made to the farmer via PoS.
  • Neem Coated Urea (NCU): 100% of domestic and imported urea is mandatory to be Neem Coated to prevent diversion for industrial use and to improve nitrogen-use efficiency.
  • One Nation One Fertilizer (ONOF): All subsidized urea is sold under a single brand name, ‘Bharat Urea’, to reduce “cross-movement” and lead-distance of fertilizer bags.

8. Budgetary Allocation & Performance (Updated March 2026)

• • Self-Sufficiency Goal: 6 new mega-plants (Gorakhpur, Sindri, Barauni, Ramagundam, Talcher, and Matix) have added 76.2 LMTPA capacity.
  • Production: India reached a record urea production of 31.4 MMT in 2024-25, aiming to eliminate imports by the end of 2026.
  • Budget 2026-27: Significant focus on Nano Urea (liquid) through 3 lakh PM-Kisan Samriddhi Kendras to reduce the traditional bulk-urea subsidy bill.

UPSC Prelims Traps Trap 1: The “NBS” Confusion. The question may state that Urea is covered under the Nutrient Based Subsidy (NBS). False. Only P&K (Phosphatic and Potassic) fertilizers are under NBS. Urea has its own separate subsidy regime. Trap 2: Funding Type. A trap may describe it as Centrally Sponsored. False. It is a Central Sector Scheme (100% Central funding). Trap 3: DBT Recipient. A statement might say “The subsidy is transferred directly to the farmer’s bank account.” False. The subsidy is transferred to the Fertilizer Company after the sale is verified via the farmer’s Aadhaar. Trap 4: Price Control. It might claim that companies are free to fix the price of Urea based on market costs. False. Urea is the only fertilizer whose MRP is statutorily fixed by the Government. Trap 5: Brand Name. A statement may suggest that IFFCO or NFL can sell urea under their own brand names. False. Under ONOF, they must use the ‘Bharat’ brand, with company logos occupying only 1/3rd of the bag space.

 2. Nutrient Based Subsidy (NBS)

1. Nodal Ministry & Department

• • Ministry: Ministry of Chemicals and Fertilizers.
  • Department: Department of Fertilizers.

2. Context

• • Launch: April 2010.
  • Rationale: To move away from product-based subsidies to nutrient-based ones for P&K (Phosphatic and Potassic) fertilizers, ensuring balanced soil health.
  • 2026 Update: The Union Budget 2026-27 and the Cabinet (Jan 2026) approved updated NBS rates for Rabi 2025-26 with an outlay of ₹37,952 crore.

3. Objectives

• • To promote the balanced use of fertilizers (NPK ratio).
  • To improve agricultural productivity and soil health.
  • To ensure the availability of P&K fertilizers at affordable prices.

4. Type of Scheme

• • Central Sector Scheme (100% funded by the Central Government).

5. Target Beneficiaries

• • Farmers (through subsidized MRP).
  • Fertilizer manufacturers/importers (who receive the subsidy).

6. Eligibility Criteria

• • Applies to 25+ grades of P&K fertilizers (like DAP, MOP, SSP).
  • New Additions (2025-26): Includes Ammonium Sulphate and innovative fortified grades (Zinc/Boron).

7. Key Features/Provisions

• • Fixed Subsidy: Government announces a fixed subsidy (per kg of nutrient) for Nitrogen (N), Phosphate (P), Potash (K), and Sulphur (S).
  • Decontrolled MRP: Unlike Urea, the MRP of P&K fertilizers is not fixed by the government; companies set the price at “reasonable” levels.
  • Fortification: Provides higher subsidy for fertilizers fortified with micro-nutrients like Boron and Zinc.

8. Budgetary Allocation & Performance (Updated March 2026)

• • Outlay: Over ₹2.04 lakh crore allocated cumulatively (2022-2025).
  • Performance: Successful expansion of domestic DAP production by 50% since 2014.

UPSC Prelims Traps Trap 1: “It covers Urea.” False. Urea is strictly excluded from NBS and has its own separate regime. Trap 2: “The government fixes the MRP for DAP.” False. MRP is decontrolled; the government only fixes the subsidy rate. Trap 3: “Subsidy is given per bag.” False. It is calculated per kg of nutrient (N, P, K, S) present in the fertilizer. Trap 4: “It is a Centrally Sponsored Scheme.” False. It is a Central Sector Scheme.

3. Production Linked Incentive (PLI) Schemes (Pharma)

1. Nodal Ministry & Department

• • Ministry: Ministry of Chemicals and Fertilizers.
  • Department: Department of Pharmaceuticals (DoP).

2. Context

• • Launch: Phase I (Bulk Drugs) in 2020; Phase II (Pharmaceuticals) in 2021.
  • Why: To reduce “Import Dependence” on China for APIs (Active Pharmaceutical Ingredients) and KSMs (Key Starting Materials).

3. Objectives

• • To achieve Atmanirbhar Bharat in life-saving drugs.
  • To attract large-scale investments and create high-value jobs.

4. Type of Scheme

• • Central Sector Scheme.

5. Target Beneficiaries

• • Large pharmaceutical companies and MSMEs involved in the manufacture of 41 critical bulk drugs.

6. Eligibility Criteria

• • Must meet minimum threshold investment and incremental sales targets.
  • Product must be in the approved list (e.g., Penicillin G, Streptomycin).

7. Key Features/Provisions

• • Incentive: 10% to 20% on incremental sales (depending on the drug category).
  • Tenure: Up to FY 2028-29.
  • Greenfield Projects: Requires setting up of new manufacturing facilities.

8. Budgetary Allocation & Performance (Updated March 2026)

• • Performance: As of March 13, 2026, 38 projects have been commissioned, resulting in 56,800 MTPA domestic capacity.
  • Outlay: ₹15,000 crore for PLI 2.0.

UPSC Prelims Traps Trap 1: “Incentives are given on total sales.” False. Incentives are only on incremental sales (growth over base year). Trap 2: “It covers all drugs.” False. It only covers identified critical APIs, KSMs, and high-value products. Trap 3: “Only private companies are eligible.” False. PSUs can also participate.

 4. Biopharma SHAKTI

(Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation)

1. Nodal Ministry & Department

• • Ministry: Ministry of Chemicals and Fertilizers.
  • Department: Department of Pharmaceuticals.

2. Context & Rationale

• • Disease Shift: India’s disease burden is shifting toward Non-Communicable Diseases (NCDs) like cancer and diabetes, which require complex biologic treatments.
  • Global Opportunity: With patents worth $300 billion set to expire by 2030, India aims to capture a significant share of the global biosimilars market.
  • Goal: To capture 5% of the global biopharmaceutical market share and support a $100 billion biotech economy.

3. Key Pillars & Provisions

A. Financial Outlay

• • ₹10,000 Crore allocated over five years (starting FY 2026–27) to build an end-to-end ecosystem.

B. Non-Animal Methodologies (NAMs) A unique feature of this scheme is the shift from traditional animal testing to advanced human-relevant models:

• • Organoids: Lab-grown “mini-organs.”
  • Organ-on-a-chip: Microchips that mimic human organ functions.
  • 3D Bioprinting & AI: Using computer modeling for drug safety.
  • Benefits: Reduces drug development costs by 10–26% and speeds up identification of drug candidates by ~20%.

C. Infrastructure & Research

• • NIPER Expansion: Establishment of 3 new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrading 7 existing ones into Centers of Excellence.
  • Clinical Trials: Creation of a national network of 1,000+ accredited clinical trial sites to accelerate advanced trials.

D. Regulatory Reform

• • Reinforcing the CDSCO (Central Drugs Standard Control Organisation) with a dedicated “Scientific Review Cadre” to speed up approvals and align them with international timelines.

4. Type of Scheme

• • Central Sector Scheme (CS).

5. Target Beneficiaries

• • Pharmaceutical companies, biotech startups, and research institutions.
  • Ultimately, patients suffering from cancer, diabetes, and autoimmune disorders through more affordable treatments.

UPSC Prelims Traps Trap 1: “It is under the Ministry of Health and Family Welfare.” False. It is under the Ministry of Chemicals and Fertilizers. Trap 2: “It focuses on generic chemical drugs.” False. It specifically targets high-value biologics and biosimilars. Trap 3: “It promotes traditional animal testing for faster results.” False. It specifically encourages the move toward Non-Animal Methodologies (NAMs) like organ-on-a-chip.

Spread the Word